ASCO, JUNE 2022 Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer (ESBC) Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy
IMMUNOLOGY 2022, MAY 2022 Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy - Abstract IMV, Inc.
AACR, APRIL 2022 Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer NK cells are involved in promoting anti-tumor responses to DPX-peptide immunotherapy
AACR, APRIL 2022 NK cells are involved in promoting anti-tumor responses to DPX-peptide immunotherapy - Moamen Bydoun, Senior Research Scientist, IMV Inc.
Research and Development Day, February 2022 Why previous cancer vaccines have failed? IMV DPX delivery platform is different, better, and safer.
ESMO-IO, DECEMBER 2021 Translational analyses of the DeCidE1clinical study in advanced ovarian cancer patients reveal a substantial role for B cells in the clinical benefit derived from maveropepimut-S (MVP-S) treatment
SITC, NOVEMBER 2021 Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer
AACR-NCI-EORTC, OCTOBER 2021 DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients
AACR-NCI-EORTC, OCTOBER 2021 Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients
